RMB, I don't think you understand what I'm saying. If the Hikma label is a partial label, so is the Teva label. Every generic would have a partial label. If Hikma is found to be guilty of induced infringement, based in part on the label, all generic companies have inappropriate labels. A settlement is not a rational strategy. Remember, it has been determined that at the pleading stage all of this is now a matter of fact not law.
Now do you follow?
Sleven,
Market Data 
Markets 
AI
